The coronavirus pandemic besieged the world for more than two years, forcing countries around the globe to shut down and quarantine in a bid to halt the spread of the virus. Nearly two and a half years after authorities in Wuhan, China, reported the outbreak of a novel coronavirus, the world is starting to emerge from the pandemic.
Governments have been lifting lockdown restrictions and mask mandates for the past couple of months, allowing their residents to finally get out of their homes after months and months of isolation. However, the coronavirus pandemic and the subsequent lockdowns seem to have had a peculiar effect.
Other viruses and diseases that had been suppressed by COVID-19 social restrictions are re-emerging in strange and unusual ways. Health experts opine that limited exposure and reduced immunity to infectious diseases due to social restrictions may have increased society’s vulnerability to novel disease outbreaks. This includes the respiratory syncytial virus, influenza, tuberculosis, adenovirus and even monkeypox.
For instance, the United States had extremely mild winter flu seasons in 2020 and 2021 in terms of hospital admissions and deaths. But as COVID-19 restrictions reduce, seasonal influenza cases started to rise. By the time spring and summer rolled around, influenza cases were at an all-time high. Yale-New Haven Hospital’s associate medical director for infection prevention states that it is extremely rare for a flu season to extend into June in the U.S. and that COVID-19 played a role. With people out and about after months of self-isolation and mask wearing, he said that viruses are now behaving in odd ways we haven’t seen before.
Aside from the common cold, there has also been an uptick in the respiratory syncytial virus during the summer in the U.S., Japan and Europe, even though the virus is more common in the winter.
Early this year, an outbreak of adenovirus 41 is thought to have been the cause of a mysterious and acute liver disease in children. Over in Washington State, hospitals have been dealing with the worst tuberculosis flare-up since the late 1990s. Not to mention the recent monkeypox outbreak in the West. Despite this rare viral infection being endemic to Central and West Africa, there are now more than 1,000 confirmed and suspected cases in 29 countries where the virus is not endemic.
The U.S. is currently grappling with two genetically distinct variants of the monkeypox virus. The World Health Organization posits that the virus may have been circulating undetected for months or even years in society.
These reemerging viral infections make a strong case justifying why entities such as AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) continue to invest heavily into discovery programs aimed at finding clinical solutions to any complexities that are caused by various viral diseases.
NOTE TO INVESTORS: The latest news and updates relating to AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) are available in the company’s newsroom at https://ibn.fm/AREVF
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork.